Wegovy 2mg — the dose that doesn't exist, and why that matters

The myth that a round "2mg" dose exists, and where it probably comes from

The confusion is understandable. People researching weight-loss injections online encounter a blur of numbers: semaglutide 2.4mg, Ozempic 2mg, tirzepatide 2.5mg. Ozempic (the diabetes version of semaglutide, not licensed for weight management) does have a 2mg dose. That's the most likely source of the crossed wires.

Wegovy and Ozempic both contain semaglutide, but they are separate products with separate licences. The semaglutide overview covers both in detail, but the short version is this: using the wrong dose descriptor when searching for a weight-loss medicine online is exactly how people end up on unregulated websites offering unlicensed products. Legitimate UK pharmacies stock only the authorised strengths. If a listing says "semaglutide 2mg for weight loss," that's a red flag worth pausing on.

The MHRA has warned publicly about counterfeit and mislabelled weight-loss pens, and NHS guidance on semaglutide is clear that prescription and clinical assessment come before any supply. A seller happy to describe the product inaccurately probably has other corners being cut too.

What the actual Wegovy dose steps do, and why 2.4mg is earned, not assumed

The titration schedule exists for a reason. Starting at 0.25mg gives the body time to adjust to semaglutide's effect on gut motility; nausea and other gastrointestinal symptoms are more manageable when the dose climbs gradually. Roughly every four weeks a prescriber assesses how treatment is going before confirming the next step.

The sequence (0.25mg, 0.5mg, 1.0mg, 1.7mg, 2.4mg) isn't arbitrary. Earlier steps in the schedule are part of the therapeutic journey, not a staging post to skip. Some people find a lower maintenance dose works well for them; others need the full 2.4mg to reach meaningful weight loss. That clinical judgment sits with the prescriber, not the patient.

Since April 2026, there's now a further option. The MHRA approved a dedicated single-dose 7.2mg Wegovy pen on 14 April 2026 (three times the previous ceiling) for adults with a BMI of 30 or above. The 2.0mg figure people sometimes search for is nowhere on this ladder. What is on it is a meaningful escalation pathway supported by clinical evidence, including around 20.7% average weight loss over 72 weeks at 7.2mg.

Who is actually eligible, and what a prescriber looks at beyond BMI

Under the UK licence, Wegovy is indicated for adults with a BMI of 30 or above, or 27 to 29.9 alongside at least one weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. Different thresholds at the lower end of the eligibility range are explored separately.

A BMI number alone doesn't decide suitability. A prescriber also looks at medical history, current medicines, and contraindications, for example, Wegovy isn't recommended during pregnancy, breastfeeding or when actively trying to conceive, and it isn't licensed for under-18s. People with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome would not be suitable candidates.

NICE's guidance on semaglutide for weight management (TA875) adds further criteria for NHS access, specialist services, up to two years of treatment, multidisciplinary support. Privately, the licence criteria apply directly, and no referral is required. Payday or a Monday morning after a bank holiday weekend: whenever you decide to look into this seriously, a private consultation can usually move quickly once you're ready.

The side effects worth knowing before your first pen arrives

The most common effects are gastrointestinal: nausea, loose stools, constipation, indigestion and occasional vomiting. These tend to be most noticeable in the first week or two after a dose increase and settle for most people as the body adapts. Fatigue, headache and dizziness are also reported.

Pancreatitis is a less common but more serious risk. In January 2026, the MHRA issued a Drug Safety Update specifically highlighting acute pancreatitis as a known side effect of GLP-1 medicines: get urgent medical help for severe, persistent stomach pain that extends towards the back, especially if vomiting is present. The MHRA's Yellow Card scheme is the place to report any suspected reactions, patients can do this directly, without going through a GP.

The practical guide to getting the most from Wegovy covers how to support treatment with diet and activity. Questions about your specific situation are always best directed to a prescriber who has seen your full medical picture.

If you'd like to explore whether Wegovy is clinically suitable for you, start your free consultation with a prescriber from our clinical team. Every consultation at nume is reviewed by a GPhC-registered Independent Prescriber, a real clinician, the same day.